Notice of extraordinary general meeting 11 March 2016
(Oslo, Norway, 19 February 2016) Bionor Pharma ASA (OSE: BIONOR) will conduct an extraordinary general meeting (EGM) on 11 March 2016 at 12:00 CET at Kronprinsesse Märthas Plass 1, Oslo, Norway, 9th floor.
Notice of the extraordinary general meeting is attached hereto and includes detailed registration and proxy instructions for the EGM.
Please refer to the stock exchange announcement issued on 12 February 2016 for more information.
Please click here to download EGM notice.
For online registration of attendance and advance voting please click here.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine
Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by significantly reducing latent HIV reservoir and further demonstrated control of viral load. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.